Breaking News, Collaborations & Alliances

Cobra Biologics Helps Alligator Bio Complete Phase I Trial

maxXpress platform used to enable rapid and high-yielding expression of protein ADC-1013

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Cobra Biologics said that the immuno-oncology antibody ADC-1013 manufactured as part of the company’s cell line development program for Alligator Bioscience AB, a Swedish biotechnology company, has completed its first Phase 1 clinical trial. Cobra developed the cell line expressing ADC-1013 for CD40 agonistic immuno-oncology using its maxXpress service. The maxXpress platform uses Ubiquitous Chromatin Opening Element (UCOE) technology that enables rapid and high-yielding production of correct...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters